RU2018138639A - Способ, чип и их применение - Google Patents

Способ, чип и их применение Download PDF

Info

Publication number
RU2018138639A
RU2018138639A RU2018138639A RU2018138639A RU2018138639A RU 2018138639 A RU2018138639 A RU 2018138639A RU 2018138639 A RU2018138639 A RU 2018138639A RU 2018138639 A RU2018138639 A RU 2018138639A RU 2018138639 A RU2018138639 A RU 2018138639A
Authority
RU
Russia
Prior art keywords
week
biomarkers
weeks
pancreatic cancer
fragment
Prior art date
Application number
RU2018138639A
Other languages
English (en)
Russian (ru)
Other versions
RU2018138639A3 (cg-RX-API-DMAC10.html
Inventor
Карл БОРРЕБАЕК
Анна Сандстрем ГЕРДССОН
Кристер ВИНГРЕН
Original Assignee
Иммуновиа Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммуновиа Аб filed Critical Иммуновиа Аб
Publication of RU2018138639A publication Critical patent/RU2018138639A/ru
Publication of RU2018138639A3 publication Critical patent/RU2018138639A3/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
RU2018138639A 2016-05-10 2017-05-10 Способ, чип и их применение RU2018138639A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608192.9 2016-05-10
GBGB1608192.9A GB201608192D0 (en) 2016-05-10 2016-05-10 Method, array and use thereof
PCT/EP2017/061202 WO2017194613A2 (en) 2016-05-10 2017-05-10 Method, array and use thereof

Publications (2)

Publication Number Publication Date
RU2018138639A true RU2018138639A (ru) 2020-06-10
RU2018138639A3 RU2018138639A3 (cg-RX-API-DMAC10.html) 2020-10-30

Family

ID=56297465

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018138639A RU2018138639A (ru) 2016-05-10 2017-05-10 Способ, чип и их применение

Country Status (13)

Country Link
US (2) US20200011872A1 (cg-RX-API-DMAC10.html)
EP (2) EP3907509A3 (cg-RX-API-DMAC10.html)
JP (2) JP2019516981A (cg-RX-API-DMAC10.html)
KR (1) KR20190005858A (cg-RX-API-DMAC10.html)
CN (1) CN109564221A (cg-RX-API-DMAC10.html)
AU (1) AU2017261762A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018073178A2 (cg-RX-API-DMAC10.html)
CA (1) CA3022022A1 (cg-RX-API-DMAC10.html)
GB (1) GB201608192D0 (cg-RX-API-DMAC10.html)
IL (1) IL262824A (cg-RX-API-DMAC10.html)
MX (1) MX2018013621A (cg-RX-API-DMAC10.html)
RU (1) RU2018138639A (cg-RX-API-DMAC10.html)
WO (1) WO2017194613A2 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008231575A1 (en) 2007-03-27 2008-10-02 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3127569A1 (en) * 2019-02-18 2020-08-27 The University Of Liverpool Method of diagnosis
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
WO2022109105A1 (en) * 2020-11-18 2022-05-27 Pandion Operations, Inc. Madcam targeted therapeutics and uses thereof
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
WO2022204332A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising c-met agonist antibodies and methods for use in ocular treatment
KR102651557B1 (ko) * 2022-09-28 2024-03-27 주식회사 휴벳바이오 췌장암 진단용 조성물
CN117305244B (zh) * 2023-03-28 2025-02-28 湖南省肿瘤医院 人胰腺癌细胞株及其应用
CN120177800B (zh) * 2025-05-23 2025-10-10 四川大学 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039578B1 (en) 1980-05-02 1985-04-10 Edward P. Davis Leg aid device
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
DE60325541D1 (de) * 2002-10-31 2009-02-12 Hoffmann La Roche Verfahren/Präparat zur Erkennung von Pankreaskrebs
US9005613B2 (en) * 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
WO2007013360A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Pancreatic cancer related gene cst6 and gabrp
AU2008231575A1 (en) * 2007-03-27 2008-10-02 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
MX350533B (es) * 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
WO2013052480A1 (en) * 2011-10-03 2013-04-11 The Board Of Regents Of The University Of Texas System Marker-based prognostic risk score in colon cancer
US20150018235A1 (en) * 2012-01-13 2015-01-15 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
KR20140094180A (ko) * 2013-01-21 2014-07-30 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 폴리펩타이드 또는 항체를 포함하는 췌장암 진단용 조성물
CA2902841A1 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
US20160055297A1 (en) * 2013-04-17 2016-02-25 Lg Electronics Inc. Method for extracting biomarker for diagnosing pancreatic cancer, computing device therefor, biomarker for diagnosing pancreatic cancer and device for diagnosing pancreatic cancer including the same
BR112016007037B1 (pt) * 2013-10-01 2023-12-26 National Cancer Center Método para detectar câncer pancreático
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
WO2015171736A2 (en) * 2014-05-07 2015-11-12 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
KR20150129932A (ko) * 2014-05-12 2015-11-23 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트
CN105092845A (zh) * 2015-07-10 2015-11-25 深圳市贝沃德克生物技术研究院有限公司 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof

Also Published As

Publication number Publication date
US20220206004A1 (en) 2022-06-30
RU2018138639A3 (cg-RX-API-DMAC10.html) 2020-10-30
JP2021165745A (ja) 2021-10-14
GB201608192D0 (en) 2016-06-22
EP3907509A2 (en) 2021-11-10
EP3907509A3 (en) 2021-12-29
KR20190005858A (ko) 2019-01-16
US20200011872A1 (en) 2020-01-09
WO2017194613A2 (en) 2017-11-16
BR112018073178A2 (pt) 2019-02-19
EP3455632A2 (en) 2019-03-20
JP2019516981A (ja) 2019-06-20
CN109564221A (zh) 2019-04-02
WO2017194613A3 (en) 2017-12-21
CA3022022A1 (en) 2017-11-16
MX2018013621A (es) 2019-04-25
AU2017261762A1 (en) 2018-11-15
IL262824A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
JP2019516981A5 (cg-RX-API-DMAC10.html)
KR101788414B1 (ko) 간암 조기 진단용 바이오마커 및 그 용도
US8273539B2 (en) Extracellular and membrane-associated prostate cancer markers
RU2019123695A (ru) Способы, массивы и их применение
KR102289278B1 (ko) 췌장암 진단용 바이오마커 패널 및 그 용도
JP6072768B2 (ja) 川崎病の診断マーカーおよび治療標的
JP2020507760A5 (cg-RX-API-DMAC10.html)
EP2784511A1 (en) Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
WO2017146529A1 (ko) 대장암 진단용 조성물과 진단 마커 검출 방법
KR101478826B1 (ko) 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트
CN109975549B (zh) 肿瘤来源IgG在胰腺癌诊断或预后中的用途
KR100925147B1 (ko) 폐암 진단용 마커
WO2012081007A2 (en) Methods of diagnosing and treating pancreatic cancer
KR20200025544A (ko) 유방암 진단용 바이오마커 및 이의 용도
JP6639408B2 (ja) デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法
US20140248637A1 (en) Composition for diagnosis of lung cancer and diagnosis kit of lung cancer
KR102171189B1 (ko) 담도암의 진단 또는 예후 예측용 바이오마커 및 이의 활용
CN117120847A (zh) 肺癌的检测方法
CN106461665A (zh) 用于诊断胰腺癌的包括用于特异性结合至补体因子b蛋白的抗体和用于特异性结合至糖类抗原19‑9蛋白的抗体的试剂盒
KR101995189B1 (ko) 비침습적 체외진단을 위한 간암 진단용 바이오마커 조성물 및 이를 포함하는 키트
KR101878974B1 (ko) 신장암 진단용 조성물과 진단 마커 검출 방법
EP3698138B1 (en) Assay and kit for the diagnosis of ovarian carcinoma
US20160069883A1 (en) Biomarkers for detection of breast cancer
JP6769596B2 (ja) 膀胱癌診断薬及び生体試料の判定方法
CN113789387B (zh) 标志物在诊断腹主动脉瘤中的用途

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20211220